Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 6:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,203 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Part I Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

NCT04041310
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®
Biological · Drug
Lead sponsor
Nouscom SRL
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)

NCT03656718
View directory record Official record
Conditions
Neoplasms by Site
Interventions
nivolumab, rHuPH20
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
10
States / cities
Atlanta, Georgia • Rockville, Maryland • Detroit, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 12, 2026, 6:36 PM EDT
Active, not recruiting Not applicable Interventional

SMART Stepped Care Management for Low Back Pain in the Military Health System

NCT04172038
View directory record Official record
Conditions
Low Back Pain, Chronic Pain, Military Personnel, Veterans
Interventions
Physical Therapy, Move 2 Health (M2H), MORE Mindfulness
Behavioral
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
4
States / cities
Schofield Barracks, Hawaii • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

NCT02665143
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
Nintedanib and AML induction
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 12, 2026, 6:36 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

NCT06946017
View directory record Official record
Conditions
Digestive Health, Quality of Life
Interventions
Fermented dairy protein with prebiotic fiber supplement, Control placebo
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 50 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 1 Interventional

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

NCT05564650
View directory record Official record
Conditions
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Interventions
Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Biological · Drug · Procedure + 1 more
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 4 Interventional Results available

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

NCT01172418
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Alemtuzumab, Daclizumab, Thymoglobulin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 12, 2026, 6:36 PM EDT
Recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions
Surovatamig
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Fullerton, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Recruiting Phase 1 Interventional

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

NCT04943848
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions
rHSC-DIPGVax, Balstilimab, Zalifrelimab
Biological · Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Orange, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stress and Coping in Caregivers of Younger Patients With Cancer

NCT02725385
View directory record Official record
Conditions
Anxiety, Depression
Interventions
Laboratory Biomarker Analysis, Physiologic Testing, Questionnaire Administration
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2018 · Synced Sep 12, 2026, 6:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

NCT04435691
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Magrolimab, Venetoclax
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma

NCT04167618
View directory record Official record
Conditions
Medulloblastoma, Childhood
Interventions
177Lu-DTPA-omburtamab
Drug
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
3 Years to 19 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Rochester, Minnesota • New York, New York • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

NCT01677741
View directory record Official record
Conditions
Neoplasms, Brain
Interventions
Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 17 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
8
States / cities
Phoenix, Arizona • Orange, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 1 Interventional

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

NCT01625351
View directory record Official record
Conditions
Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
Interventions
alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
Drug · Biological · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Terminated Phase 3 Interventional

Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

NCT04684511
View directory record Official record
Conditions
Hemophilic Arthropathy
Interventions
TRM-201 (Rofecoxib), Placebo
Drug
Lead sponsor
Tremeau Pharmceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 12, 2026, 6:36 PM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 1 Interventional Results available

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm
Interventions
18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 12, 2026, 6:36 PM EDT
Not listed Phase 1Phase 2 Interventional

Lorlatinib Combinations in Lung Cancer

NCT04292119
View directory record Official record
Conditions
Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement, Relapsed Cancer, MET Amplification, Resistant Cancer, NSCLC
Interventions
Lorlatinib, Crizotinib, Binimetinib, TNO155
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 12, 2026, 6:36 PM EDT
Active, not recruiting Phase 1 Interventional

Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors

NCT02789228
View directory record Official record
Conditions
Solid Tumors
Interventions
Tumor associated antigen lymphocytes (TAA-CTL)
Biological
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Months to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia

NCT06980428
View directory record Official record
Conditions
Healthy Participants, Dyslipidemia
Interventions
AZD4954, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Glendale, California • Inverness, Florida • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Terminated Phase 1 Interventional

A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

NCT01080664
View directory record Official record
Conditions
Haematological Malignancies
Interventions
AS703569
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2013 · Synced Sep 12, 2026, 6:36 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899
View directory record Official record
Conditions
Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies
Interventions
Durvalumab / Tremelimumab Combination Therapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 12, 2026, 6:36 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

NCT02488044
View directory record Official record
Conditions
Arginase I Deficiency, Hyperargininemia
Interventions
AEB1102
Drug
Lead sponsor
Aeglea Biotherapeutics
Industry
Eligibility
2 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Stanford, California • Gainesville, Florida • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Sep 12, 2026, 6:36 PM EDT